Abstract
Drug discovery is costly and time-consuming, but it will become easier and simpler if a drug could be developed from an old one with well-documented investigations associated with pharmacology, pharmacokinetics, toxicology and clinical safety. In terms of hematological malignancies, several successful drugs have been discovered and developed from old ones such as arsenic trioxide for acute promyelocytic leukemia and thalidomide for multiple myeloma. In this review, we discussed the latest advancement in exploring old drugs for the treatment of hematological malignancies.
Keywords: Drug repositioning, drug discovery, old drug, hematological malignancy, drug, arsenic trioxide, pharmacological, therapeutic, dysfunction, methotrexate, rheumatoid arthritis, hematological malignancies
Current Medicinal Chemistry
Title: Exploring Old Drugs for the Treatment of Hematological Malignancies
Volume: 18 Issue: 10
Author(s): F. Gan, B. Cao, D. Wu, Z. Chen, T. Hou and X. Mao
Affiliation:
Keywords: Drug repositioning, drug discovery, old drug, hematological malignancy, drug, arsenic trioxide, pharmacological, therapeutic, dysfunction, methotrexate, rheumatoid arthritis, hematological malignancies
Abstract: Drug discovery is costly and time-consuming, but it will become easier and simpler if a drug could be developed from an old one with well-documented investigations associated with pharmacology, pharmacokinetics, toxicology and clinical safety. In terms of hematological malignancies, several successful drugs have been discovered and developed from old ones such as arsenic trioxide for acute promyelocytic leukemia and thalidomide for multiple myeloma. In this review, we discussed the latest advancement in exploring old drugs for the treatment of hematological malignancies.
Export Options
About this article
Cite this article as:
Gan F., Cao B., Wu D., Chen Z., Hou T. and Mao X., Exploring Old Drugs for the Treatment of Hematological Malignancies, Current Medicinal Chemistry 2011; 18 (10) . https://dx.doi.org/10.2174/092986711795328427
DOI https://dx.doi.org/10.2174/092986711795328427 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Current Medicinal Chemistry Adalimumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Hematopoietic Stem Cells: Transcriptional Regulation, Ex Vivo Expansion and Clinical Application
Current Molecular Medicine RNA Interference in Cancer: Targeting the Anti-Apoptotic Protein c-FLIP for Drug Discovery
Mini-Reviews in Medicinal Chemistry Crosstalk between Oxidative and Nitrosative Stress and Arterial Stiffness
Current Vascular Pharmacology Deregulated Expression of miR-224 and its Target Gene: CD59 Predicts Outcome of Diffuse Large B-cell Lymphoma Patients Treated with R-CHOP
Current Cancer Drug Targets Hepatocarcinogenesis and Ceramide/Cholesterol Metabolism
Anti-Cancer Agents in Medicinal Chemistry Breast Cancer: Current Developments in Molecular Approaches to Diagnosis and Treatment
Recent Patents on Anti-Cancer Drug Discovery Emergence of Azole Therapy for Cancer Associated Fungal Infections and Their Potential Human Toxicity
The Natural Products Journal Fluorescent Cisplatin Analogues and Cytotoxic Activity
Current Medicinal Chemistry Editorial (Thematic Issue: Targeting Epithelial-to-Mesenchymal Transition for Cancer Therapy)
Current Pharmaceutical Design HIV-Related Lymphoproliferative Diseases in the Era of Combination Antiretroviral Therapy
Cardiovascular & Hematological Disorders-Drug Targets Immunotherapeutic and Immunoregulatory Drugs in Haematologic Malignancies
Current Topics in Medicinal Chemistry Myelodysplastic/Myeloproliferative Neoplasms
Current Cancer Therapy Reviews Evaluating Treatment Response of Chronic Myeloid Leukemia: Emerging Science and Technology
Current Cancer Drug Targets Thalidomide in Multiple Myeloma
Current Pharmaceutical Biotechnology Safety of the Thrombopoiesis-Stimulating Agents for the Treatment of Immune Thrombocytopenia
Current Drug Safety Editorial: Advances in Epithelial Ovarian Cancer Therapy
Current Pharmaceutical Design Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy Focal Adhesion Kinase as a Therapeutic Target of Bortezomib
Anti-Cancer Agents in Medicinal Chemistry